Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia.
University of Zagreb School of Medicine, Zagreb, Croatia.
Acta Clin Croat. 2022 Oct;61(Suppl 3):45-50. doi: 10.20471/acc.2022.61.s3.6.
Since its introduction 20 years ago, robotic radical prostatectomy has become a standard of care in the treatment of localized prostate cancer in many Centers. Until recently, they have all been performed by the only available robotic platform. Senhance is a novel robotic platform that was approved for clinical use. The term Senhance was used to systematically search PubMed and Scopus databases for relevant articles that were afterward filtered for appropriate designs and data reports. There were two reports that met all of the criteria and were included in the review. Both studies were designed as prospective case series with a total of 234 patients where the data including operative data and oncological outcomes were reported. The average operative time ranged between 180 and 195 min, with estimated blood loss between 250 and 300 mL. There was 3 Clavien - Dindo grade III, and 1 Clavien - DIndo grade IV complication reported. One of the studies compared it with laparoscopy, but no significant difference in operative time and blood loss was found. Both studies concluded that the Senhance is a feasible and safe robotic platform for radical prostatectomy.
自 20 年前推出以来，机器人根治性前列腺切除术已成为许多中心治疗局限性前列腺癌的标准治疗方法。直到最近，所有这些手术都是通过唯一可用的机器人平台完成的。Senhance 是一种新型的机器人平台，已获得临床使用批准。使用 Senhance 这个术语系统地搜索了 PubMed 和 Scopus 数据库，以查找相关文章，然后根据适当的设计和数据报告对其进行了筛选。有两份报告符合所有标准，并被纳入了综述。这两项研究均设计为前瞻性病例系列研究，共有 234 例患者，报告了包括手术数据和肿瘤学结果在内的数据。平均手术时间在 180 到 195 分钟之间，估计失血量在 250 到 300 毫升之间。有 3 例 Clavien - Dindo III 级和 1 例 Clavien - Dindo IV 级并发症报告。其中一项研究将其与腹腔镜进行了比较，但在手术时间和失血量方面没有发现显著差异。这两项研究的结论是，Senhance 是一种可行且安全的机器人根治性前列腺切除术平台。
